GB8513754D0
(en)
*
|
1985-05-31 |
1985-07-03 |
Jones T R |
Anti-cancer quinazoline derivatives
|
GB8625019D0
(en)
*
|
1986-10-18 |
1986-11-19 |
Wellcome Found |
Compounds
|
GB8707053D0
(en)
*
|
1987-03-25 |
1987-04-29 |
Ici Plc |
Anti-tumour agents
|
US4857530A
(en)
*
|
1987-11-03 |
1989-08-15 |
Warner-Lambert Company |
Substituted quinazolinones as anticancer agents
|
GB8727737D0
(en)
*
|
1987-11-26 |
1987-12-31 |
Ici Plc |
Antitumour agents
|
US5019577A
(en)
*
|
1988-04-15 |
1991-05-28 |
Burroughs Welcome Co. |
Novel compounds and use
|
US4940713A
(en)
*
|
1988-04-15 |
1990-07-10 |
Burroughs Wellcome Co. |
Substituted glutamic acids
|
GB8809978D0
(en)
*
|
1988-04-27 |
1988-06-02 |
Ici Plc |
Anti-tumour agents
|
EP0365763A1
(en)
*
|
1988-09-30 |
1990-05-02 |
Agouron Pharmaceuticals, Inc. |
Antiproliferative cyclic compounds
|
US5252573A
(en)
*
|
1988-12-15 |
1993-10-12 |
Imperial Chemical Industries Plc |
Anti-tumor agents
|
GB8829296D0
(en)
*
|
1988-12-15 |
1989-01-25 |
Ici Plc |
Anti-tumour compounds
|
US5286726A
(en)
*
|
1990-04-12 |
1994-02-15 |
The Regents Of The University Of Michigan |
Difluoroglutamic acid conjugates with folates and anti-folates for the treatment of neoplastic diseases
|
ZA913730B
(en)
*
|
1990-05-30 |
1992-02-26 |
Ici Plc |
Anti-tumor compounds
|
GB9013615D0
(en)
*
|
1990-06-19 |
1990-08-08 |
Wellcome Found |
Pharmaceutical compounds
|
US5290780A
(en)
*
|
1991-01-30 |
1994-03-01 |
American Cyanamid Co. |
Angiotensin II receptor blocking 2,3,6 substituted quinazolinones
|
GB9105771D0
(en)
*
|
1991-03-19 |
1991-05-01 |
Cancer Res Inst Royal |
Anti-cancer compounds
|
NZ243082A
(en)
|
1991-06-28 |
1995-02-24 |
Ici Plc |
4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
|
EP0530537B1
(en)
*
|
1991-08-12 |
1997-01-08 |
Takeda Chemical Industries, Ltd. |
Condensed pyrimidine derivatives, their production and use as antitumor agents
|
US5145854A
(en)
*
|
1991-11-27 |
1992-09-08 |
Nair Madhavan G |
1-formyl-5,8,10-trideazafolates
|
GB9205320D0
(en)
*
|
1992-03-11 |
1992-04-22 |
Ici Plc |
Anti-tumour compounds
|
GB9205907D0
(en)
*
|
1992-03-18 |
1992-04-29 |
Cancer Res Inst Royal |
Anti-cancer compounds
|
ES2049659B1
(es)
*
|
1992-10-08 |
1994-10-16 |
Ici Plc |
Una composicion farmaceutica a base de derivados de quinazolina con actividad anti-cancerigena.
|
GB9223352D0
(en)
*
|
1992-11-06 |
1992-12-23 |
Ici Plc |
Tricyclic compounds
|
GB9323290D0
(en)
|
1992-12-10 |
1994-01-05 |
Zeneca Ltd |
Quinazoline derivatives
|
US7910624B1
(en)
|
1995-03-03 |
2011-03-22 |
The Trustees Of Boston University |
Compositions for the treatment of blood disorders
|
AU696167B2
(en)
*
|
1993-10-29 |
1998-09-03 |
Trustees Of Boston University |
Physiologically stable compositions of butyric acid, and butyric acid salts and derivatives as anti-neoplastic agents
|
US6011000A
(en)
*
|
1995-03-03 |
2000-01-04 |
Perrine; Susan P. |
Compositions for the treatment of blood disorders
|
GB9508565D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
US5593999A
(en)
*
|
1995-06-07 |
1997-01-14 |
Nair; Madhavan G. |
Non-classical folate analogue inhibitors of glycinamide ribonucleotide formyltransferase (GARFT)
|
CN1282319A
(zh)
*
|
1997-10-09 |
2001-01-31 |
小野药品工业株式会社 |
氨基丁酸衍生物
|
US5912251A
(en)
*
|
1998-01-17 |
1999-06-15 |
Nair; Madhavan G. |
Metabolically inert anti-inflammatory and anti-tumor antifolates
|
CA2324426A1
(en)
*
|
1998-02-11 |
1999-08-19 |
Douglas V. Faller |
Compositions and methods for the treatment of cystic fibrosis
|
GB9904275D0
(en)
|
1999-02-24 |
1999-04-21 |
Cancer Res Campaign Tech |
Anti-cancer compounds
|
US7230000B1
(en)
*
|
1999-10-27 |
2007-06-12 |
Cytokinetics, Incorporated |
Methods and compositions utilizing quinazolinones
|
US7671200B2
(en)
*
|
1999-10-27 |
2010-03-02 |
Cytokinetics, Inc. |
Quinazolinone KSP inhibitors
|
US6545004B1
(en)
|
1999-10-27 |
2003-04-08 |
Cytokinetics, Inc. |
Methods and compositions utilizing quinazolinones
|
UA74803C2
(uk)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
Стійкий поліморф гідрохлориду n-(3-етинілфеніл)-6,7-біс(2-метоксіетокси)-4-хіназолінаміну, спосіб його одержання (варіанти) та фармацевтичне застосування
|
US6143776A
(en)
*
|
2000-02-02 |
2000-11-07 |
Sunesis Pharmaceuticals, Inc. |
Tosylproline analogs as thymidylate synthase inhibitors
|
WO2003000194A2
(en)
|
2001-06-21 |
2003-01-03 |
Pfizer Inc. |
Thienopyridine and thienopyrimidine anticancer agents
|
DE60237902D1
(de)
|
2001-08-31 |
2010-11-18 |
Btg Int Ltd |
ANTIKREBS-CYCLOPENTAiG CHINAZOLINE-DERIVATE
|
WO2003020300A1
(en)
|
2001-08-31 |
2003-03-13 |
Btg International Limited |
Use of cyclopenta[g]quinazoline derivatives for treating cancer
|
US6753428B2
(en)
*
|
2001-11-20 |
2004-06-22 |
Cytokinetics, Inc. |
Process for the racemization of chiral quinazolinones
|
JP2005529076A
(ja)
*
|
2002-02-15 |
2005-09-29 |
サイトキネティクス・インコーポレーテッド |
キナゾリノンの合成
|
CN101486682B
(zh)
|
2002-03-13 |
2013-08-14 |
阵列生物制药公司 |
作为mek抑制剂的n3烷基化苯并咪唑衍生物
|
US7214800B2
(en)
|
2002-05-09 |
2007-05-08 |
Cytokinetics, Inc. |
Compounds, compositions, and methods
|
MXPA04011074A
(es)
*
|
2002-05-09 |
2005-06-08 |
Cytokinetics Inc |
Compuestos de pirimidinona, composiciones y metodos.
|
US7038048B2
(en)
*
|
2002-05-23 |
2006-05-02 |
Cytokinetics, Inc. |
3H-pyridopyrimidin-4-one compounds, compositions, and methods of their use
|
CA2489367A1
(en)
*
|
2002-06-14 |
2003-12-24 |
Cytokinetics, Inc. |
Compounds, compositions, and methods
|
AU2003256805A1
(en)
*
|
2002-07-23 |
2004-02-09 |
Cytokinetics, Inc. |
Compounds compositions and methods
|
WO2004018058A2
(en)
*
|
2002-08-21 |
2004-03-04 |
Cytokinetics, Inc. |
Compounds, compositions, and methods
|
PA8580301A1
(es)
|
2002-08-28 |
2005-05-24 |
Pfizer Prod Inc |
Nuevos derivados de benzoimidazol utiles como agentes antiproliferativos
|
AU2003277079A1
(en)
*
|
2002-09-30 |
2004-05-04 |
Cytokinetics, Inc. |
Compounds, compositions, and methods
|
ATE458731T1
(de)
|
2002-12-20 |
2010-03-15 |
Pfizer Prod Inc |
Pyrimidin-derivate zur behandlung von anormalem zellwachstum
|
US7144907B2
(en)
|
2003-09-03 |
2006-12-05 |
Array Biopharma Inc. |
Heterocyclic inhibitors of MEK and methods of use thereof
|
US20050197327A1
(en)
*
|
2003-11-03 |
2005-09-08 |
Gustave Bergnes |
Compounds, compositions, and methods
|
JP2007510660A
(ja)
*
|
2003-11-07 |
2007-04-26 |
サイトキネティクス・インコーポレーテッド |
化合物、組成物及び方法
|
NZ547481A
(en)
|
2003-11-19 |
2009-12-24 |
Array Biopharma Inc |
Heterocyclic inhibitors of mek and methods of use thereof
|
JP2007513154A
(ja)
*
|
2003-12-08 |
2007-05-24 |
サイトキネティクス・インコーポレーテッド |
化合物、組成物及び方法
|
MXPA06013805A
(es)
|
2004-05-27 |
2007-02-02 |
Pfizer Prod Inc |
Derivados de pirrolopirimidina de utilidad en el tratamiento contra el cancer.
|
WO2006029385A2
(en)
|
2004-09-08 |
2006-03-16 |
Chelsea Therapeutics, Inc. |
Quinazoline derivatives as metabolically inert antifolate compounds.
|
US7429667B2
(en)
|
2005-01-20 |
2008-09-30 |
Ardea Biosciences, Inc. |
Phenylamino isothiazole carboxamidines as MEK inhibitors
|
EA012970B1
(ru)
|
2005-04-26 |
2010-02-26 |
Пфайзер Инк. |
Антитела против р-кадгерина
|
TW201238952A
(en)
|
2005-05-18 |
2012-10-01 |
Array Biopharma Inc |
Heterocyclic inhibitors of MEK and methods of use thereof
|
US8101799B2
(en)
|
2005-07-21 |
2012-01-24 |
Ardea Biosciences |
Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
|
JP5161777B2
(ja)
|
2005-09-07 |
2013-03-13 |
アムジェン フレモント インク. |
アクチビン受容体様キナーゼ−1に対するヒトモノクローナル抗体
|
US7842836B2
(en)
|
2006-04-11 |
2010-11-30 |
Ardea Biosciences |
N-aryl-N'alkyl sulfamides as MEK inhibitors
|
ATE483463T1
(de)
|
2006-04-18 |
2010-10-15 |
Ardea Biosciences Inc |
Pyridonsulfonamide und pyridonsulfamide als mek- hemmer
|
EP2258700A1
(en)
|
2006-05-09 |
2010-12-08 |
Pfizer Products Inc. |
Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
|
EP2125818A1
(en)
|
2007-01-19 |
2009-12-02 |
Chelsea Therapeutics, Inc. |
New classical antifolates
|
WO2010105112A1
(en)
*
|
2009-03-11 |
2010-09-16 |
Hemaquest Pharmaceuticals, Inc. |
Detection of short-chain fatty acids in biological samples
|
EP2411366B8
(en)
|
2009-03-27 |
2015-07-15 |
Ardea Biosciences, Inc. |
Dihydropyridin sulfonamides and dihydropyridin sulfamides as mek inhibitors
|
SMT201700430T1
(it)
|
2009-06-25 |
2018-01-11 |
Alkermes Pharma Ireland Ltd |
Composti eterociclici per il trattamento di disturbi neurologici e psicologici
|
WO2011027249A2
(en)
|
2009-09-01 |
2011-03-10 |
Pfizer Inc. |
Benzimidazole derivatives
|
WO2011038224A1
(en)
|
2009-09-24 |
2011-03-31 |
Trustees Of Boston University |
Methods for treating viral disorders
|
KR20120103604A
(ko)
|
2009-11-06 |
2012-09-19 |
첼시 쎄라퓨틱스, 인코포레이티드 |
효소 저해성 화합물
|
WO2011068403A2
(en)
|
2009-12-02 |
2011-06-09 |
Ultimorphix Technologies B.V. |
Novel n-{3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamjne salts
|
US8618068B2
(en)
|
2009-12-08 |
2013-12-31 |
Trustees Of Boston University |
Methods and low dose regimens for treating red blood cell disorders
|
AU2010339689B2
(en)
*
|
2010-01-07 |
2015-02-19 |
Alkermes Pharma Ireland Limited |
Quaternary ammonium salt prodrugs
|
US8754072B2
(en)
|
2010-02-12 |
2014-06-17 |
Pfizer Inc. |
Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
|
US20110245154A1
(en)
|
2010-03-11 |
2011-10-06 |
Hemaquest Pharmaceuticals, Inc. |
Methods and Compositions for Treating Viral or Virally-Induced Conditions
|
WO2011163594A2
(en)
|
2010-06-24 |
2011-12-29 |
Alkermes, Inc. |
Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
|
PL2611300T3
(pl)
|
2010-09-03 |
2016-10-31 |
|
Podstawione skondensowane pochodne dihydropirymidynonów
|
EP2630134B9
(en)
|
2010-10-20 |
2018-04-18 |
Pfizer Inc |
Pyridine-2- derivatives as smoothened receptor modulators
|
US8658652B2
(en)
|
2010-12-07 |
2014-02-25 |
Chelsea Therapeutics, Inc. |
Antifolate combinations
|
GB201103578D0
(en)
|
2011-03-02 |
2011-04-13 |
Sabrepharm Ltd |
Dipyridinium derivatives
|
LT3156056T
(lt)
|
2011-03-18 |
2024-02-26 |
Alkermes Pharma Ireland Limited |
Farmacinės kompozicijos, apimančios sorbitano esterius
|
BR112014006840A2
(pt)
|
2011-09-22 |
2017-04-04 |
Pfizer |
derivados de pirrolopirimidina e purina
|
CN102424679B
(zh)
*
|
2011-11-15 |
2014-07-30 |
扬子江药业集团有限公司 |
一种雷替曲塞的制备方法
|
WO2013142205A1
(en)
|
2012-03-19 |
2013-09-26 |
Alkermes Pharma Ireland Limited |
Pharmaceutical compositions comprising benzyl alcohol
|
JP6219918B2
(ja)
|
2012-03-19 |
2017-10-25 |
アルカームス ファーマ アイルランド リミテッド |
グリセロールエステルを含む医薬組成物
|
US10004807B2
(en)
|
2012-03-19 |
2018-06-26 |
Alkermes Pharma Ireland Limited |
Pharmaceutical compositions comprising fatty acid esters
|
JP6654042B2
(ja)
|
2012-09-19 |
2020-02-26 |
アルカームス ファーマ アイルランド リミテッド |
貯蔵安定性が改善された医薬組成物
|
EP3650023A1
(en)
|
2013-10-04 |
2020-05-13 |
Aptose Biosciences Inc. |
Compositions for treating cancers
|
UA115388C2
(uk)
|
2013-11-21 |
2017-10-25 |
Пфайзер Інк. |
2,6-заміщені пуринові похідні та їх застосування в лікуванні проліферативних захворювань
|
US9452131B2
(en)
|
2014-03-20 |
2016-09-27 |
Alkermes Pharma Ireland Limited |
Aripiprazole formulations having increased injection speeds
|
WO2015155624A1
(en)
|
2014-04-10 |
2015-10-15 |
Pfizer Inc. |
Dihydropyrrolopyrimidine derivatives
|
AP2016009530A0
(en)
|
2014-04-30 |
2016-10-31 |
Pfizer |
Cycloalkyl-linked diheterocycle derivatives
|
WO2016001789A1
(en)
|
2014-06-30 |
2016-01-07 |
Pfizer Inc. |
Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
|
ES2718175T3
(es)
|
2014-12-02 |
2019-06-28 |
Lilly Co Eli |
Compuestos de 1-oxo-1,2-dihidroisoquinolin-7-il-(tiofen-2-il-5-sustituido)-sulfonamida, formulaciones que contienen esos compuestos, y su uso como inhibidores de AICARFT en el tratamiento de cánceres
|
JP6621477B2
(ja)
|
2014-12-18 |
2019-12-18 |
ファイザー・インク |
ピリミジンおよびトリアジン誘導体ならびにaxl阻害薬としてのそれらの使用
|
CN104447724B
(zh)
*
|
2014-12-31 |
2017-11-10 |
四川峨嵋山药业有限公司 |
一种雷替曲塞的精制方法
|
CA2991044A1
(en)
|
2015-06-29 |
2017-01-05 |
Verastem, Inc. |
Therapeutic compositions, combinations, and methods of use
|
WO2017009751A1
(en)
|
2015-07-15 |
2017-01-19 |
Pfizer Inc. |
Pyrimidine derivatives
|
GB2543550A
(en)
|
2015-10-21 |
2017-04-26 |
Hox Therapeutics Ltd |
Peptides
|
US20190008869A1
(en)
|
2016-01-13 |
2019-01-10 |
Acerta Pharma B.V. |
Therapeutic Combinations of an Antifolate and a BTK Inhibitor
|
CN106957312B
(zh)
*
|
2016-12-29 |
2019-11-01 |
南京正大天晴制药有限公司 |
雷替曲塞水合物晶型及其制备方法
|
CN106957311B
(zh)
*
|
2016-12-29 |
2020-03-31 |
南京正大天晴制药有限公司 |
雷替曲塞的溶剂化物及其制备方法
|
JP7384812B2
(ja)
|
2018-03-05 |
2023-11-21 |
アルカームス ファーマ アイルランド リミテッド |
アリピプラゾール投与戦略
|
CN109734698B
(zh)
*
|
2019-01-25 |
2020-07-17 |
宏冠生物药业有限公司 |
一种雷替曲塞关键中间体的合成工艺
|
US20220226322A1
(en)
|
2019-05-31 |
2022-07-21 |
Viracta Subsidiary, Inc. |
Methods of treating virally associated cancers with histone deacetylase inhibitors
|
PT3986890T
(pt)
|
2019-06-18 |
2024-01-17 |
Ctxt Pty Ltd |
Derivados de benzisoxazol sulfonamida
|
AU2020295006B2
(en)
|
2019-06-19 |
2023-11-09 |
Ctxt Pty Ltd |
Cycloalkyl and heterocycloalkyl benzisoxazole sulfonamide derivatives
|